Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer
文献类型：期刊论文
| 作者 | Luo, LingJie1,2,3; Lin, Caiji1,2,3; Wang, Pengfei1,2,3,6; Cao, Danli1,2,3; Lin, Yiru1,2,3; Wang, Wenxue1,2,3; Zhao, Yufan1,2,3; Shi, Yongwei1,2,3; Gao, Zixiang1,2,3; Kang, Xin1,2,3 |
| 刊名 | JOURNAL OF CANCER
 |
| 出版日期 | 2023 |
| 卷号 | 14期号:12页码:2315-2328 |
| ISSN号 | 1837-9664 |
| 关键词 | Immune checkpoint inhibitor Phytochemicals Combination therapy Immune-related adverse events Predictive biomarker Gut microbiota |
| DOI | 10.7150/jca.85966 |
| 通讯作者 | Liu, Huidi(hdliu@hrbmu.edu.cn) ; Liu, Shu-Lin(slliu@hrbmu.edu.cn) |
| 英文摘要 | Immune checkpoint inhibitor (ICI) therapy has dramatically changed cancer treatment, opening novel opportunities to cure malignant diseases. To date, most prevalently targeted immune checkpoints are programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with many others being under extensive investigations. However, according to available data, only a fraction of patients may respond to ICI therapy. Additionally, this therapy may cause severe adverse immune-related side effects, such as diarrhea, headache, muscle weakness, rash, hepatitis and leucopenia, although most of them are not fatal, they can affect the patient's treatment outcome and quality of life. On the other hand, growing evidence has shown that phytochemicals with anticancer effects may combine ICI therapy to augment the safety and effectiveness of the treatment against cancer while reducing the adverse side effects. In this review, we summarize the state of art in the various experiments and clinical application of ICIs plus phytochemicals, with a focus on their combined use as a novel therapeutic strategy to cure cancer. |
| WOS关键词 | CELL LUNG-CANCER ; METASTATIC UROTHELIAL CARCINOMA ; LONG-TERM SAFETY ; OPEN-LABEL ; INDUCED EXPRESSION ; PD-L1 EXPRESSION ; GUT MICROBIOTA ; IN-VITRO ; CURCUMIN ; NIVOLUMAB |
| 资助项目 | National Natural Science Foundation of China[82020108022] ; National Natural Science Foundation of China[82104217] ; College Students' Innovation and Entrepreneurship Project in Heilongjiang Province[S202010226035] ; National College Students' Innovation and Entrepreneurship Project[201910226005] ; Young Innovative Talents of Heilongjiang Province Universities[UNPYSCT-2018064] ; China Postdoctoral Science Foundation[2018M630380] ; Heilongjiang Postdoctoral Financial Assistance[LBH-Z18198] ; Merit -based Funding for Returned Oversea Students in Heilongjiang Province[2019-YQ-08] ; College of Pharmacy, Harbin Medical University, Excellent Young Talents Funding[CoV- 202007] ; Harbin Medical University College of Pharmacy COVID-19 Funding for Medicine Research[LBH- Q21139] ; HMU Marshal Initiative Funding ; [2019QD0026] ; [HMUMIF-21026] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | IVYSPRING INT PUBL |
| WOS记录号 | WOS:001040943000003 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/306884]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Liu, Huidi; Liu, Shu-Lin |
| 作者单位 | 1.Harbin Med Univ, Coll Pharm, Genom Res Ctr, Key Lab Gut Microbiota & Pharmacogen Heilongjiang, Harbin 150081, Peoples R China 2.Harbin Med Univ, Natl Key Lab Frigid Zone Cardiovasc Dis NKLFZCD Co, Harbin 150081, Peoples R China 3.Harbin Med Univ, Univ Calgary, Ctr Infect & Genom, Cumming Sch Med, Harbin 150081, Peoples R China 4.Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada 5.Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB T2N 4N1, Canada 6.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China 7.Harbin Med Univ, State Prov Key Lab Biomed Pharmaceut China, Genom Res Ctr Key Lab Gut Microbiota & Pharmacogen, Coll Pharm, 157 Baojian Rd, Harbin 150081, Peoples R China |
| 推荐引用方式 GB/T 7714 | Luo, LingJie,Lin, Caiji,Wang, Pengfei,et al. Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer[J]. JOURNAL OF CANCER,2023,14(12):2315-2328. |
| APA | Luo, LingJie.,Lin, Caiji.,Wang, Pengfei.,Cao, Danli.,Lin, Yiru.,...&Wang, Jiaxing.(2023).Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer.JOURNAL OF CANCER,14(12),2315-2328. |
| MLA | Luo, LingJie,et al."Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer".JOURNAL OF CANCER 14.12(2023):2315-2328. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。